xRead - September 2022

Wise et al.

Page 386

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Study Year LOE Study design Study groups Clinical endpoint Conclusion 2 Placebo

Nasal symptoms DSCG performed better than placebo. Symptom score, medication use

No difference, except for in-season use of medications in DSCG group.

Nasal symptoms No difference between DSCG and placebo. Symptom score, medication use

DSCG performed better than placebo.

Nasal symptoms DSCG performed better than placebo.

1 DSCG 31.2 mg, 6 times per day (n = 26); 2 Budesonide BID, 400 μ g/day (n = 30) Nasal symptoms Budesonide performed better than DSCG. 1 FP 200 μ g QD (n = 110); Nasal/ocular symptoms, medication use

FP better in all except nasal discharge. No difference in medication use.

Symptom scores, nPIF MF performed best.

Lange et al. 1361 2005 2b RCT, no placebo SAR, 18–65 years old: 1 MF 200 μ g QD (n = 41); 2 Levocabastine 200 μ g BID (n = 40); placebo

Nizami & Baboo 1375 1977 1b DBRCT, crossover SAR, 7–59 years old (n = 92): 1 DSCG 10 mg QID; 2 Placebo

1 DSCG 4%, 6 times per day (n = 17); 2 Placebo (n = 17)

Warland & Kapstad 1359 1977 1b DBRCT, crossover PAR, 15–57 years old (n = 17): 1 DSCG 10 mg QID; 2 Placebo

Cohan et al. 1360 1976 1b DBRCT, crossover PAR, 16–37 years old: 1 DSCG 4%, 6 times per day; 2 Placebo

1 DSCG 10 mg QID (n = 35); 2 Placebo (n = 41)

3 DSCG 5.6 mg QID (n = 42)

2 DSCG 5.2 mg QID (n = 108)

Posey & Nelson 1376 1977 1b DBRCT SAR, 12–54 years old:

Knight et al. 1377 1976 1b DBRCT SAR:

SAR, 6–15 years old: SAR:

placebo

Fisher 1362 1994 2b RCT, blinded, no

Bousquet et al. 1363 1993 2b DBRCT, no

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.